MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Recommendation of "Buy" from Analysts

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has been given a consensus rating of "Buy" by the seven research firms that are presently covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have covered the stock in the last year is $74.50.

MLTX has been the topic of a number of research analyst reports. Needham & Company LLC reissued a "buy" rating and issued a $66.00 target price on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. Wolfe Research upgraded MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 target price for the company in a report on Monday, May 19th. Wedbush reissued an "outperform" rating and set a $80.00 price target (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. Finally, Royal Bank Of Canada restated an "outperform" rating and issued a $67.00 price objective on shares of MoonLake Immunotherapeutics in a report on Tuesday, June 3rd.

MoonLake Immunotherapeutics Trading Down 2.8%

MoonLake Immunotherapeutics stock traded down $1.39 during mid-day trading on Friday, hitting $47.50. The company's stock had a trading volume of 496,401 shares, compared to its average volume of 385,496. MoonLake Immunotherapeutics has a 1 year low of $31.42 and a 1 year high of $58.26. The company has a current ratio of 21.11, a quick ratio of 21.11 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $3.04 billion, a PE ratio of -20.65 and a beta of 1.27. The stock's fifty day moving average is $42.72 and its two-hundred day moving average is $42.65.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.13. During the same quarter in the previous year, the business earned ($0.22) earnings per share. On average, analysts anticipate that MoonLake Immunotherapeutics will post -1.79 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MLTX. Deutsche Bank AG boosted its holdings in MoonLake Immunotherapeutics by 59.8% in the fourth quarter. Deutsche Bank AG now owns 903 shares of the company's stock valued at $49,000 after purchasing an additional 338 shares in the last quarter. US Bancorp DE boosted its holdings in shares of MoonLake Immunotherapeutics by 114.4% in the 1st quarter. US Bancorp DE now owns 2,208 shares of the company's stock valued at $86,000 after buying an additional 1,178 shares in the last quarter. Quarry LP purchased a new position in shares of MoonLake Immunotherapeutics in the 1st quarter valued at $94,000. Birchview Capital LP purchased a new stake in MoonLake Immunotherapeutics in the fourth quarter valued at $217,000. Finally, Advisors Asset Management Inc. boosted its stake in MoonLake Immunotherapeutics by 81.7% in the first quarter. Advisors Asset Management Inc. now owns 4,009 shares of the company's stock valued at $157,000 after acquiring an additional 1,803 shares in the last quarter. 93.85% of the stock is owned by institutional investors and hedge funds.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.